摘要:
PROBLEM TO BE SOLVED: To provide an anti-fatigue agent comprising amino acid composition composed of specific amino acids in specified amounts which can prevent both of muscle fatigue and nerve strain concurrently.SOLUTION: As for the types and the ratio of the amounts of the amino acids contained in the amino acid composition, the amino acid composition preferably contains 30 to 200 pts.wt. of proline, 60 to 140 pts.wt. of glycine, 50 to 260 pts.wt. of alanine, 50 to 130 pts.wt. of lysine, 30 to 75 pts.wt. of tryptophan and 20 to 40 pts.wt. of histidine, more preferably further comprises 3 to 75 pts.wt. of tyrosine and 15 to 45 pts.wt. of arginine, still more preferably further contains 30 to 55 pts.wt. of valine, 35 to 60 pts.wt. of leucine and 25 to 60 pts.wt. of isoleucine. In the anti-fatigue agent, the amino acid composition as an active ingredient is administered in the range of 0.01 to 8 g/kg/day.
摘要:
The invention provides intradialytic parenteral nutrition (IDPN) solutions with low carbohydrate for the treatment of malnutrition in dialysis patients. The IDPN solutions of the invention are particularly advantageous for the treatment of malnutrition in patients who are diabetic or suffer from other glucose management related pathologies or patients who require strict fluid management.
摘要:
PROBLEM TO BE SOLVED: To provide antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9) and methods of using and making the antigen binding proteins.SOLUTION: Described herein are isolated neutralizing antigen binding proteins that bind to a PCSK9 protein comprising a specific amino acid sequence and decrease the LDLR lowering effect of PCSK9 on LDLR. Also described are methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9. Also described are methods of detecting the amount of PCSK9 in a sample by using an antigen binding protein to PCSK9.
摘要:
The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof.